| ID Source | ID |
|---|---|
| PubMed CID | 161302 |
| MeSH ID | M0081889 |
| Synonym |
|---|
| inchi=1/c16h15clo6/c1-7-4-8(18)5-11(22-3)16(7)15(20)12-10(21-2)6-9(19)13(17)14(12)23-16/h5-7,19h,4h2,1-3h |
| 6-demethylgriseofulvin |
| FT-0665721 |
| 7-chloro-6-hydroxy-3',4-dimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione |
| 7-chloranyl-3',4-dimethoxy-5'-methyl-6-oxidanyl-spiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione |
| 7-chloro-6-hydroxy-3',4-dimethoxy-5'-methylspiro[benzofuran-2,4'-cyclohex-2-ene]-1',3-dione |
| A816609 |
| spiro[benzofuran-2(3h),1'-[2]cyclohexene]-3,4'-dione, 7-chloro-6-hydroxy-2',4-dimethoxy-6'-methyl-, (1's-trans)- |
| SYNGDIBHUPXIQA-UHFFFAOYSA-N |
| 7-chloro-6-hydroxy-2',4-dimethoxy-6'-methyl-3h-spiro[1-benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione |
| 7-chloro-6-hydroxy-2',4-dimethoxy-6'-methyl-3h-spiro[1-benzofuran-2,1'-cyclohex[2]ene]-3,4'-dione |
| DTXSID30942222 |
| PD143302 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The bioavailability of griseofulvin was followed in twelve healthy volunteers by measuring the urinary excretion of the major metabolite 6-demethylgriseolfulvin, after each volunteer had ingested one 500 mg griseofulvin tablet under (1) fasting conditions, (2) immediately after a typical low-fat and (3) high-fat Nigerian meals." | ( Fat contents of meals and bioavailability of griseofulvin in man. Ogunbona, FA; Olawoye, OS; Smith, IF, 1985) | 0.27 |
| " The bioavailability of griseofulvin was higher following the ultramicrosize formulation when 64% of the dose was recovered (via metabolites) versus 52% after the microsize preparation." | ( Human plasma and skin blister fluid levels of griseofulvin following a single oral dose. Korting, HC; Mutschler, E; Schäfer-Korting, M, 1985) | 0.27 |
| "The bioavailability of griseofulvin in three different brands, two microfine forms (Gricin = G, Likuden = L), and one ultramicrofine form (Gris-PEG = GP), was determined in plasma and urine in six healthy volunteers in a crossover study and compared with in vitro liberation data." | ( The in vitro liberation and the bioavailability of different brands of griseofulvin in plasma and urine in man. Feller, K; Le Petit, G; Pachaly, C; Terhaag, B, 1985) | 0.27 |
| " On repeated administration, the bioavailability of griseofulvin was significantly lower from the microsize formulation; the urinary recovery of total 6-DMG was 33." | ( Human plasma and skin blister fluid levels of griseofulvin after its repeated administration. Korting, HC; Mutschler, E; Schäfer-Korting, M, 1985) | 0.27 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The elimination of this main metabolite after dosing with L is lower (0." | ( The in vitro liberation and the bioavailability of different brands of griseofulvin in plasma and urine in man. Feller, K; Le Petit, G; Pachaly, C; Terhaag, B, 1985) | 0.27 |
| " The concentration of unbound griseofulvin in these body fluids was identical throughout the entire dosage interval." | ( Human plasma and skin blister fluid levels of griseofulvin after its repeated administration. Korting, HC; Mutschler, E; Schäfer-Korting, M, 1985) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||